|
|
| |
 |
Product Growth Strategy |
|
|
| |
|
| |
|
| |
 |
Obio Pharmaceutical Announces
Product Growth Strategy
Research Based Emerging Pharmaceutical Company
Now with Two Patented Drugs &
Multinational Investor Pool and Prominent Research Team
Drive Novel and Safe Blockbuster
Antiviral Influenza Drug Discovery to Be Launched in 2011
(Hong Kong, February 16, 2009) — Obio Pharmaceutical Holdings Ltd
(“Obio”/ “the Company”) announced its business growth ticket to the international
pharmaceutical arena. With a strong product pipeline in drug development, backed up
by strong international investors including Yangtze Ventures Limited (New World Group,
Shui On Group, Tai Sang Land Properties Limited, Yu Hwa Chinese Products Group,
YangtzeKiang Garment Manufacturing Company Limited), Avanta Capital, Group of
prominent Swiss investors, Simplex Capital Fund (Korean based), Japanese investors Mr.
Haruyoshi Taguchi and Mr. Takatoshi Nakamura, PE Lifestyle (HK) Limited (subsidiary of
Singapore listed company -Goldtron Limited), Obio is taking off and adopting more
aggressive measures to drive the growth of the Company.
The research based emerging pharmaceutical company has just had a
facelift by appointing seasoned pharmaceutical executives to the Board so as to further
overhaul its research and development activities and heighten its competitive edge.
External research collaborations will continue to be the pillars of the Company to boost
innovations and confirm experimental data in the future.
Mr. Abraham Chan, Director of the Company, said on the press conference of
the Company dated February 9, 2009, “Obio plans to reinforce the global development
strategy by focusing its researches on the globally prevalent but underserved diseases such
as diabetes and influenza.”
Amongst the drug candidates in the portfolio relating to the influenza virus and
life-style diseases, Obio has managed to get two drugs patented at present. Drug DC9703,
which targets Diabetes II, has been granted patents in USA and South Africa. The
Company has also successfully patented the AK20 in China, which treats Nonalcoholic
Steatohepatitis (NASH/ nonalcoholic fatty liver disease).
Besides the two patented drugs, Obio has also discovered an antiviral drug
candidate - TG21 that could tackle avian and human influenza virus. Thanks to the US Food
and Drug Administration (FDA) and EU European Medicines Agency (EMA) previous
approval of the active ingredient of TG21 as an orphan drug, its safety profile is assured. As
cases of resistance to the mainstream medical intervention- TamifluTM are on the rise, TG21
can be considered an alternative drug preparing for possible pandemic threat. TG21 works
on a different mechanism to that of both TamifluTM and RelenzaTM , which are
Neuraminidase Inhibitors. TG21 does not work on the same target so the influenza virus is
less likely to develop resistance to TG21.
A US Patent Attorney has prepared a patentability report for TG21, application
of patents has also been filed on TG21 and pending approval. As a drug research and
discovery company, Obio is in process to apply for a fast track mode to accelerate drug
registration given the needs of effective treatment for lethal influenza viruses are unmet,
and actively negotiating partnership with large pharmaceuticals companies to produce
the drug.
Apart from the aforementioned drug candidates, the Company continues to
push research of its candidates in life-style and Parkinson disease arenas. The Company
believes that its research focus will achieve the Company vision to research and develop
novel drugs, and bring them into the market through co-development with other
prestigious pharmaceutical companies.
Dr. Bill Chan, Director and Chief Technical Officer of the Company, said, “All
the drug candidates on hand should be able to capture the attention from the
pharmaceutical industries. Some of them have high chance to become blockbuster drugs
after analyzing the market demand. Now, Obio holds all the aces and ready to launch its
products; the growth strategy in launching the blockbuster drugs together with other
pharmaceutical companies will certainly accelerate the company growth at and could
then further reinvest in the drug discovery process.”
Mr. K C Cheng, Director and Chief Financial Officer said, “Obio’s board is
satisfied with the current development and strives to achieve the Company’s mission by
putting the company in a listed company platform as soon as possible and continues to
research, develop and commercialize novel medicines for the underserved diseases
affecting millions of patients worldwide.”
About Obio Pharmaceutical Holdings Limited
Obio is a Hong Kong-based international pharmaceutical company. Obio targets to
research, develop and commercialize novel medicines for the underserved diseases
affecting millions of patients worldwide. Obio is a knowledge-based, technology driven
pharmaceutical company, dedicated to the research and development of novel drugs,
and bringing them into the market through co-development with other prestigious
pharmaceutical companies. Obio’s research center is located at Beijing and researches
are often contracted to outside prestigious medical institutes for confirmation of
experiment data.
Details please refer to www.obiopharma.com.
For more information, please contact
JOVIAN Financial Communications Ltd
Angel Y Y Yeung / Alice Choi
Tel： +852 2154 7898 Fax: +852 2854 2012
Email: alice.choi@joviancomm.com / angel.yeung@joviancomm.com
|
|
 |
|
|
|
